The FDA’s approval of Moderna’s mFLUSIVA marks another major expansion of modified mRNA technology. Approved on August 5 for adults aged 50 and older in the United States, the product is intended for use during the 2026–2027 influenza season and is expected to appear on shelves in the coming weeks.
This deserves immediate attention. Despite all of the harms we witnessed during the COVID-19 rollout, the same dangerous technological platform is now being introduced into routine seasonal influenza inoculation. The United States may be first, but applications are also being considered elsewhere, making this an international issue. Please warn everyone of the dangers and do not take these shots.
… …
…